TY - JOUR
T1 - Peptichemio in pretreated patients with plasmacell neoplasms
AU - Paccagnella, Adriano
AU - Salvagno, Luigi
AU - Chiarion-Sileni, Vanna
AU - Bolzonella, Sandro
AU - de Besi, Pietro
AU - Frizzarin, Michela
AU - Pappagallo, Giovanni L.
AU - Fosser, Vinicio P.
AU - Fornasiero, Adriano
AU - Segati, Romana
AU - Fiorentino, Mario V.
PY - 1986
Y1 - 1986
N2 - Twenty-one patients with alkylator-resistant plasmacell neoplasms were treated with Peptichemio (PTC) at a dose of 40 mg/m2 for 3 days every 3 weeks or, in the case of persistent leukopenia and/or thrombocytopenia, at the single dose of 70 mg/m2 every 2-3 weeks according to haematological recovery. Seventeen patients, 10 with multiple myeloma and seven with extramedullary plasmacytoma (EMP), were fully evaluable. Six of 17 patients (35%) responded: three of seven EMP patients had a complete remission and 3 of 10 multiple myeloma patients had an objective response 50%. The median duration of response was 8.5 months. An EMP patient obtained a complete response lasting for 16 months. The most frequent toxic effect were phlebosclerosis, occurring in all the patients, and myelosuppression, which was severe in only one case. PTC appears to be an active drug in patients with plasmacell neoplams even if resistant to alkylating agents.
AB - Twenty-one patients with alkylator-resistant plasmacell neoplasms were treated with Peptichemio (PTC) at a dose of 40 mg/m2 for 3 days every 3 weeks or, in the case of persistent leukopenia and/or thrombocytopenia, at the single dose of 70 mg/m2 every 2-3 weeks according to haematological recovery. Seventeen patients, 10 with multiple myeloma and seven with extramedullary plasmacytoma (EMP), were fully evaluable. Six of 17 patients (35%) responded: three of seven EMP patients had a complete remission and 3 of 10 multiple myeloma patients had an objective response 50%. The median duration of response was 8.5 months. An EMP patient obtained a complete response lasting for 16 months. The most frequent toxic effect were phlebosclerosis, occurring in all the patients, and myelosuppression, which was severe in only one case. PTC appears to be an active drug in patients with plasmacell neoplams even if resistant to alkylating agents.
UR - http://www.scopus.com/inward/record.url?scp=0022483689&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022483689&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(86)90005-2
DO - 10.1016/0277-5379(86)90005-2
M3 - Article
C2 - 3780812
AN - SCOPUS:0022483689
VL - 22
SP - 1053
EP - 1058
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 9
ER -